Communicating About OFF Episodes With Your Doctor

Similar documents
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Best Medical Treatments for Parkinson s disease

Treatment of Parkinson s Disease: Present and Future

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Medication Management & Strategies When the levodopa honeymoon is over

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

PARKINSON S MEDICATION

Evaluation and Management of Parkinson s Disease in the Older Patient

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Optimizing Clinical Communication in Parkinson s Disease:

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Medications used to treat Parkinson s disease

Parkinson s Disease. Gillian Sare

PD: Key Treatment Considerations

Parkinson s Disease Medications: Professionals Edition

Issues for Patient Discussion

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

10th Medicine Review Course st July Prakash Kumar

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension

Surgical Management of Parkinson s Disease

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)

Update in the Management of Parkinson s Disease

Dr Barry Snow. Neurologist Auckland District Health Board

What s new for diagnosing and treating Parkinson s Disease?

Key Concepts and Issues in Parkinson s Disease in 2016

Overview of Parkinson s disease Research at University of Colorado

Faculty. Joseph Friedman, MD

Parkinson s Disease Current Treatment Options

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Surgical Treatment: Patient Edition

Welcome and Introductions

SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

The Shaking Palsy of 1817

CONTINUOUS THERAPY BECAUSE LIFE GOESON

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

DYSKINESIA SYMPTOM TRACKER

Welcome and Introductions

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Prior Authorization with Quantity Limit Program Summary

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Margo J Nell Dept Pharmacology

Parkinson s Disease medications

Non-Motor Symptoms of Parkinson s Disease

Update on Parkinson s disease and other Movement Disorders October 2018

FOR PARKINSON S DISEASE XADAGO NEXT?

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

XADAGO (safinamide) oral tablet

Acute management of in-patient Parkinson s Disease patients

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Scottish Medicines Consortium

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

LIVING. WITH PD. DAVID RYTARY patient since Fighting his symptoms. Embracing his life.

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

New Medicines Committee Briefing July 2011

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Continuous dopaminergic stimulation

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

(safinamide) tablets

DOCTOR DISCUSSION GUIDE

Drugs for Parkinson s Disease

Literature Scan: Anti-Parkinson s Agents

Surgical Treatment for Movement Disorders

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

PRODUCT MONOGRAPH. Pr PROLOPA. levodopa and benserazide capsules. 50 mg mg, 100 mg - 25 mg, 200 mg - 50mg. Pharmaceutical standard: professed

THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

BORDEAUX MDS WINTER SCHOOL FOR YOUNG

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

What is Parkinson s Disease?

Elements for a public summary

Parkinson s Disease Update

Clinical Guideline for the management of inpatients with Parkinson s disease

Deep Brain Stimulation (DBS) Surgery for Parkinson s Disease Atkinson Morley Movement Disorders Group

The PD You Don t See: Cognitive and Non-motor Symptoms

Parkinson's Disease and how you can make a difference with medication

A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Commonly encountered medications and their side effects - what the generalist needs to know

Understanding Parkinson s Disease Important information for you and your loved ones

Transcription:

Communicating About OFF Episodes With Your Doctor

Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom control waxes and wanes, with the biggest effect felt shortly after taking a dose of medication, and a decline or wearing OFF before the next dose. An OFF period is a period when the person with PD is no longer experiencing the benefit of the most recent dose of an anti-pd medication (e.g., levodopa). OFF periods are a significant feature of advancing PD, and a major source of disability when untreated. The good news is that treatment is available to help people with PD reduce OFF periods and maintain their best quality of life. How OFF periods affect you may be different from the way they affect someone else. Their effects may also change over the course of the disease, and even from day to day. That variability and unpredictability is a hallmark of living with PD. Understanding the wide range of potential OFF symptoms may improve your ability to effectively cope with OFF periods, and to better understand the potential and limitations of treatments to reduce OFF periods. The information contained in this booklet is solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient s own physician.

What Causes OFF Periods? OFF periods occur because, as PD progresses, the brain loses its ability to store and release dopamine to maintain a steady level. When brain dopamine goes down, it may result in an OFF period. Dopamine is a naturally occurring brain chemical that helps control movements and other functions. The healthy brain maintains a steady level of dopamine, allowing it to function normally. In people with PD, the cells that make dopamine die off over time. The drug levodopa is converted into dopamine and, early in the disease, the brain can use this alternative source to store and steadily release dopamine. Even though you are only taking your medication a few times a day, levodopa can provide continuous control of PD symptoms. However, as the disease progresses, the storage capacity of the remaining brain cells declines. When that occurs, the level of dopamine begins to fluctuate, rising just after taking a dose of levodopa then falling over time. Declining dopamine levels allow symptoms to reemerge before the next scheduled levodopa dose, creating an OFF period. OFF periods can occur at any time of day, but are likely to occur in the morning before you take your first dose of levodopa, since many hours have passed since your last dose. What Symptoms Am I Likely to Have During OFF Periods? The symptoms you experience during OFF periods include those you are familiar with as part of your PD including motor (movement-related) and non-motor (non-movement) symptoms. But, it s important to realize that you may also experience new or unfamiliar symptoms during OFF periods, both motor and non-motor. Recognizing the wide variety of possible symptoms will help you get the best treatment for them. Communicating About OFF Episodes With Your Doctor 1

Most people with PD are familiar with the motor symptoms including tremor, slowed movements (bradykinesia), stiffness, postural instability (increased risk of falling), and reduced dexterity. Uncontrolled motor symptoms may reduce your ability to perform many activities of daily living like getting dressed, preparing food, and working or taking part in community activities. Non-motor symptoms are no less common and no less important than motor symptoms. In fact, non-motor symptoms often have an even greater impact on quality of life than motor symptoms. Some people experience emergence of specific non-motor symptoms during OFF time. The box below lists these symptoms. Anxiety Irritability Apathy Mood changes Depression Cloudy mind or slowed thinking Fatigue Pain 2 apdaparkinson.org

OFF Periods Can Reduce Quality of Life When people with PD describe the impact of OFF periods, they usually report the return of both motor and non-motor symptoms and indicate that their symptoms affect many different aspects of their daily lives. Research has demonstrated measurable impacts of decreasing OFF periods on healthrelated quality of life. Motor and non-motor symptoms may reduce or prevent taking part in community activities or selfcare, and may affect one s self, family members, and colleagues. Anxiety is a commonly reported non-motor symptom that may have a pervasive effect on interpersonal relationships, selfimage, and ability or desire to engage in work or leisure activities. OFF periods may be unpredictable in their onset, duration, severity, and degree of symptom exacerbation, and people with PD report that this unpredictability may be one of the most debilitating aspects of OFF periods. Reducing OFF Time Begins With Sharing the Complete Picture With Your Doctor Physicians who specialize in treating PD have learned a lot about how to minimize OFF time and improve quality of life in those with advancing PD. Medication adjustment is the foundation of this stage of treatment. For maximum effectiveness, your doctor needs to hear from you and your care partner about all the ways your PD symptoms, both motor and non-motor, affect you. To understand the full picture, your doctor may ask about symptoms you never considered part of your PD including depression, anxiety, and pain. Your doctor may ask you to keep a symptom diary to track the timing and pattern of your symptoms when they occur, how they change, and which ones are the most troubling. Your care partner can provide critical information here that may not be as apparent to you, so it may be valuable to get input from him or her as well. With the complete picture in view, your doctor can work with you to develop a treatment plan to reduce the frequency, duration, and severity of your OFF periods. Communicating About OFF Episodes With Your Doctor 3

The Wide Range of Treatment Options for Reducing OFF Time and Motor Complications PD experts know there are a wide range of options for reducing OFF time. Optimizing drug therapy is the major strategy. This may include changing the dose or timing of your existing medications, adding new medications, or both. Levodopa is the mainstay of PD treatment, and adjusting your levodopa dose is usually a key strategy for decreasing OFF time. Unfortunately, increasing levodopa increases the risk for developing side effects, such as worsening dyskinesias (unwanted movements). However, many people with PD find that an increase in their dyskinesia is more tolerable than OFF periods. In addition, medications for dyskinesias can be added to a patient s regimen, if dyskinesias become problematic. Other treatment options include non-medical therapies to maximize function. These include physical therapy, voice therapy, and changes in sleep habits, all of which can help improve your abilities in the face of worsening PD. And, as discussed further below, surgery is an important option for many people with PD. Medication strategies to reduce OFF time tend to fall in two major categories those that smooth out medication delivery and those that introduce a rescue dose only when needed. Smoothing Out Medication Delivery Adjusting levodopa. Your physician may recommend increasing the dose or the number of daily doses of levodopa (levodopa is always combined with carbidopa, a drug that slows levodopa breakdown). This can reduce the amount of OFF time. You may also be advised to change your diet or the timing of your levodopa dose in relation to your meals. Levodopa must be absorbed by the gut, and high-protein meals can interfere with this uptake. Reducing protein, or waiting for a certain amount of time after a dose before you eat, can improve your uptake of levodopa. Levodopa is also available in controlled-release and extended-release formulations, which 4 apdaparkinson.org

spread out its absorption over time. The extended-release formulation has been shown to reduce OFF time compared to standard immediate-release formulations. Adding a dopamine agonist. Dopamine agonists act like dopamine and are less likely to induce dyskinesias than levodopa. Therefore, they are often used as a levodopasparing option to reduce OFF time, instead of increasing the levodopa dose. These drugs are not as effective as levodopa and the side effects may be troubling. These include drowsiness, dry mouth, dizziness, leg swelling, falling asleep without warning, and impulse control disorders (e.g., development or worsening of compulsive gambling, shopping, or sexuality). Dopamine agonists available in the United States are ropinirole, pramipexole, and rotigotine (delivered through a skin patch). Ropinirole and pramipexole are also available in long-acting versions that are taken orally once daily. Another dopamine agonist, apomorphine, is discussed on page 7. Adding a Catechol-O-methyltransferase (COMT) inhibitor. COMT inhibitors slow the breakdown of levodopa, extending the duration of benefit from a single dose, and thereby reducing OFF time. Side effects may include drowsiness, hallucinations, and dyskinesias. Two agents are available in the United States; tolcapone and entacapone. Tolcapone may increase the risk for liver toxicity in some people with PD, requiring regular liver monitoring. Entacapone is available either by itself or in a pill combined with levodopa/carbidopa. Adding an Monoamine oxidase B (MAO-B) inhibitor. MAO-B inhibitors slow the breakdown of levodopa as well, thereby decreasing OFF time. The most common side effects of MAO-B inhibitors include nausea, headache, and dyskinesia. MAO-B inhibitors approved for use in people with PD are rasagiline, safinamide, and selegiline. Safinamide is the most recently approved of the three and may have other beneficial actions in the brain besides its MAO-B inhibiting effect. Communicating About OFF Episodes With Your Doctor 5

Switching to carbidopa/levodopa gel infusion. For people with PD whose fluctuations between ON and OFF periods are not well-controlled, one alternative is to switch to a form of carbidopa/levodopa that is infused directly into the gut rather than being taken in pill form. This allows levodopa to be delivered continuously, smoothing out its level in the blood and promoting a steadier level in the brain as well. The gel infusion, called Duopa, is stored in a wearable pump, which can fit in a vest or fanny pack. It is delivered via a tube surgically placed through the abdominal wall into the intestine. Side effects include redness and infection at the abdominal site. Additionally, the tube may clog, kink, or become dislodged. Deep brain stimulation (DBS). DBS surgery is an important option for people with significant motor complications. Those who benefit the most from DBS are those who retain a good response to levodopa, but who have significant amounts of fluctuation between ON and OFF time, coupled with dyskinesias. Successful DBS treatment allows such people to lower their levodopa dose, which reduces dyskinesias without increasing OFF time. DBS requires implanting electrodes (thin metal rods) into the brain, most often in the area called the subthalamic nucleus. The electrodes receive pulses of electricity delivered by a very thin wire, which in turn is connected to a pulse generator. The pulse generator is implanted under the skin near the collarbone, and the wire runs under the skin and across the scalp to the electrodes. Risks include surgical complications, wire breakage, and infection. Rescue Doses Despite the best medical management, OFF periods and other motor complications tend to increase over time. In addition to predictable OFF periods, patients may experience OFF periods unrelated to levodopa dosing. 6 apdaparkinson.org

When OFF time becomes unpredictable despite attempts to smooth out medication delivery, introducing rescue doses of medication could be an effective strategy. An orally disintegrating tablet form of levodopa/carbidopa is available and can be used to rapidly provide a boost in levodopa to overcome OFF time. An alternative is apomorphine, a very fastacting dopamine agonist that is available in an autoinjector syringe. The wide range of treatments for OFF periods and motor complications present many options to the physician and the person with PD for a personalized treatment approach. Working with your physician and the rest of your care team can help you maintain your best quality of life as you live with PD. Experimental Approaches to Reducing OFF Time Research into better treatments for PD continues. Promising new approaches are being developed to provide more continuous levodopa delivery or to provide rescue medication options. These include: Apomorphine sublingual film Delivers apomorphine via a quickly dissolving film placed under the tongue, for rapid treatment of OFF periods. Inhaled levodopa Delivers levodopa as a dry powder than can be inhaled, rather than swallowed, for rapid treatment of OFF periods. Continuous subcutaneous delivery of a liquid form of levodopa Smooths out the fluctuations in levodopa levels that can worsen OFF periods. A novel, extended-release form of levodopa Releases the drug for up to 12 hours, providing a more continuous supply and reducing the number of individual doses that must be taken. Communicating About OFF Episodes With Your Doctor 7

Resources APDA is here to help you live with PD. The APDA network provides information and referrals, education and support programs, health and wellness activities, and events to facilitate a better quality of life for the PD community. Search the APDA website by state to connect to an Information & Referral (I&R) Center or APDA Chapter in your community at: apdaparkinson.org/community/ or (800) 223-2732. APDA provides free online publications on a variety of topics at: apdaparkinson.org/resources-support/downloadpublications/ 8 apdaparkinson.org

135 Parkinson Avenue Staten Island, NY 10305 1-800-223-2732 apdaparkinson.org Generous support for this publication was provided by: